The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial
The DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index.
Abstract
The short-acting glucagon-like peptide 1 receptor agonist exenatide reduces postprandial glycemia, partly by slowing gastric emptying, although its impact on small intestinal function is unknown. In this study, 10 healthy subjects and 10 patients with type 2 diabetes received intravenous exenatide (7.5 μg) or saline (-30 to 240 min) in a double-blind randomized crossover design. Glucose (45 g), together with 5 g 3-O-methylglucose (3-OMG) and 20 MBq (99m)Tc-sulfur colloid (total volume 200 mL), was given intraduodenally (t = 0-60 min; 3 kcal/min). Duodenal motility and flow were measured using a combined manometry-impedance catheter and small intestinal transit using scintigraphy. In both groups, duodenal pressure waves and antegrade flow events were fewer, and transit was slower with exenatide, as were the areas under the curves for serum 3-OMG and blood glucose concentrations. Insulin concentrations were initially lower with exenatide than with saline and subsequently higher. Nausea was greater in both groups with exenatide, but suppression of small intestinal motility and flow was observed even in subjects with little or no nausea. The inhibition of small intestinal motor function represents a novel mechanism by which exenatide can attenuate postprandial glycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, the action of GLP-1 and GLP-1 RAs (especially short acting) on gastric and intestinal cells causes, respectively, the deceleration of gastric emptying [31] and the reduction in intestine motility [32], which both impact the absorption of nutrients.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [32]
Citations
Cites
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“5 mg) was within the usual clinical range and was infused in a regimen shown previously to achieve steady therapeutic plasma concentrations (14,15).”
Bland, J. M., & Altman, D. G. (1995) · BMJ · doi:10.1136/bmj.310.6977.446 · Cited by 1,034
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 6×
“Exogenous GLP-1 has been reported to inhibit both fasting and postprandial duodenal motility in humans (5,6), but its impact on the flow of chyme and on small intestinal transit and glucose absorption have not previously been explored.”
InfluentialAbnormal intestinal motility in diabetics with the gastroparesis syndrome
CAMILLERI, M., & MALAGELADA, J. (1984) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1984.tb01206.x · Cited by 328 · cited 1×
“Motility indices (MIs) were calculated as ln[(sum of amplitudes 3 number of duodenal waves) + 1] (12).”
Parker, B. A., Sturm, K., MacIntosh, C. G., Feinle, C., Horowitz, M., & Chapman, I. M. (2004) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601768 · Cited by 322 · cited 1×
“Venous blood was sampled frequently for blood glucose, serum 3-OMG and insulin, and plasma C-peptide concentrations, and gastrointestinal sensations were assessed using 100-mm visual analog questionnaires (11).”
Self-citationFehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“5 mg) was within the usual clinical range and was infused in a regimen shown previously to achieve steady therapeutic plasma concentrations (14,15).”
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 1×
“The rate of gastric emptying is an established determinant of postprandial blood glucose (2), a principle illustrated by “short-acting” glucagonlike peptide 1 (GLP-1) receptor agonists, such as exenatide, where the capacity to slow gastric emptying predominates over the insulinotropic effect in the postprandial settin…”
Self-citationBonapace, E. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01988-2 · Cited by 183 · cited 1×
“Subjects remained supine under a gamma camera (7,8).”
Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160 · cited 1×
“Exogenous GLP-1 has been reported to inhibit both fasting and postprandial duodenal motility in humans (5,6), but its impact on the flow of chyme and on small intestinal transit and glucose absorption have not previously been explored.”
Little, T. J., Doran, S., Meyer, J. H., Smout, A. J. P. M., O'Donovan, D. G., Wu, K.-L., Jones, K. L., Wishart, J., Rayner, C. K., Horowitz, M., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2006 · Cited by 130 · cited 1×
“The inhibition of motility and flow that we observed with exenatide is likely to have reduced the length of small intestinal mucosa exposed to glucose (18), which is supported by our scintigraphic data, and to have diminished the thinning of the unstirred water layer, which occurs with flow of chyme (19); both phenome…”
Self-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Wharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236
Metadata
- Authors
- Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., Jones, K. L., Horowitz, M., & Rayner, C. K.
- Affiliations
- Royal Adelaide Hospital (AU)
- Corresponding author
- Rayner, Christopher K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-10-15
- Volume
- 65
- Issue
- 1
- Pages
- 269-275
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1772233715
- Cited by
- 83
- References
- 26
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 14 · 2023: 8 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 1
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- National Health and Medical Research Council of Australia
- AstraZeneca Australia
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, GLP-1 receptor agonists, small intestine motility, duodenal flow, small intestinal transit, glucose absorption, postprandial blood glucose, type 2 diabetes, 3-O-methylglucose, 99mTc-sulfur colloid scintigraphy, nausea, insulin response
- MeSH terms
- Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Duodenum, Female, Gastric Emptying, Gastrointestinal Motility, Gastrointestinal Transit, Glucose, Humans, Hypoglycemic Agents, Intestine, Small, Male, Middle Aged, Peptides, Venoms, Case-Control Studies, Cross-Over Studies, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.2337/db15-0893
- The paper
- Thazhath, S. S., Marathe, C. S., Wu, T., Chang, J., Khoo, J., Kuo, P., Checklin, H. L., Bound, M. J., Rigda, R. S., Crouch, B., Jones, K. L., Horowitz, M., & Rayner, C. K. (2016). The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes. https://doi.org/10.2337/db15-0893
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.